ExecutiveDirector,PayerStrategyandEngagement(TumorHIProgram)

## Description Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity. Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders. ## POSITION SUMMARY Provide critical leadership and above-country market access strategies including core disease models, value stories, global pricing, economic modeling, and input into Clinical Development programs. Work closely with Medical Affairs colleagues, Organized customers and Distribution providers to identify real-world and patient quality of life data capture / evidence value solutions and publication opportunities. Monitors healthcare legislative trends, understands healthcare policies, assesses implications of policies, and develops reimbursement strategies that address barriers to provider and patient access. Understands total cost of care and all aspects of reimbursement (coverage, coding, and payment) for outpatient and inpatient settings across multiple payer segments. Support the formulation of a clear and compelling disease and product value propositions through the creation of payer engagement (AMCP Dossier, Value and Economic Prop.), and p